- Home
- GMAB vs PSKY Comparison
GMAB vs PSKY Comparison
Compare GMAB & PSKY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- PSKY
- Stock Information
- Founded
- GMAB 1999
- PSKY 1914
- Country
- GMAB Denmark
- PSKY United States
- Employees
- GMAB N/A
- PSKY N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- PSKY Broadcasting
- Sector
- GMAB Health Care
- PSKY Industrials
- Exchange
- GMAB Nasdaq
- PSKY Nasdaq
- Market Cap
- GMAB 17.4B
- PSKY 19.0B
- IPO Year
- GMAB N/A
- PSKY N/A
- Fundamental
- Price
- GMAB $29.01
- PSKY $15.07
- Analyst Decision
- GMAB Strong Buy
- PSKY Sell
- Analyst Count
- GMAB 6
- PSKY 8
- Target Price
- GMAB $40.40
- PSKY $12.63
- AVG Volume (30 Days)
- GMAB 2.6M
- PSKY 5.1M
- Earning Date
- GMAB 11-06-2025
- PSKY 11-10-2025
- Dividend Yield
- GMAB N/A
- PSKY 1.31%
- EPS Growth
- GMAB 132.41
- PSKY N/A
- EPS
- GMAB 25.10
- PSKY N/A
- Revenue
- GMAB $3,845,670,022.00
- PSKY $28,756,000,000.00
- Revenue This Year
- GMAB $24.92
- PSKY $1.17
- Revenue Next Year
- GMAB $15.97
- PSKY $4.55
- P/E Ratio
- GMAB $1.16
- PSKY N/A
- Revenue Growth
- GMAB 29.57
- PSKY N/A
- 52 Week Low
- GMAB $17.24
- PSKY $9.95
- 52 Week High
- GMAB $33.65
- PSKY $20.86
- Technical
- Relative Strength Index (RSI)
- GMAB 46.20
- PSKY 38.49
- Support Level
- GMAB $28.08
- PSKY $14.65
- Resistance Level
- GMAB $29.35
- PSKY $15.40
- Average True Range (ATR)
- GMAB 0.65
- PSKY 0.49
- MACD
- GMAB -0.20
- PSKY -0.13
- Stochastic Oscillator
- GMAB 50.81
- PSKY 24.40
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About PSKY Paramount Skydance Corporation Class B Common Stock
Paramount Global operates in three global business segments: TV media, filmed entertainment, and direct to consumer. The TV media business includes television production studios and various broadcast and cable networks, including CBS, 15 owned CBS affiliates, Paramount, Nickelodeon, MTV, BET, and VH1. Filmed entertainment consists multiple film studios, most importantly Paramount Pictures. The film studios produce and distribute movies that they license to movie theaters and other media outlets. Direct to consumer includes the Paramount+, Pluto TV, and BET+ streaming services. Much of the content on Paramount's streaming platforms is created by the production studios housed within the firm's other two business segments.